Advances & Updates
The latest offering from the IGCS Education Committee comes from a new Work Group, led by Dr. Wendel Naumann (USA). This group collaborates with our industry partners year-round to provide our community with the latest “Advances & Updates” regarding current and future medicine and technology in gynecologic cancer care.
This offering is supported in part by Intuitive.
Our first educational offering from the Advances & Updates Work Group is a recorded discussion with the authors of the recently published paper, The shift from inpatient to outpatient hysterectomy for endometrial cancer in the United States: trends, enabling factors, cost, and safety.
In this video discussion, Prof. Dr. Rainer Kimmig is joined by Dr. Andrea Mariani and Dr. Carrie Langstraat to discuss the IJGC article which observed a 41.3% shift from inpatient to outpatient hysterectomy (p<0.0001), an increase in robotic hysterectomy, and a decrease in abdominal hysterectomy.
They discuss:
- The effects of robotic surgery in the context of rising number of outpatient treatment
- complication rate of robotic surgery compared to other approaches with respect to Clavien- Dindo
- Patient perspectives on outpatient vs. inpatient treatment
- The cost in countries not adequately reimbursing outpatient treatment
- Global implications of robotic technology
Podcast
The IGCS Education360 Podcast features interview segments with international leading experts discussing the latest advances and updates in gynecologic cancer therapeutics, surgery, and applications to clinical practice. The contributors provide commentary on the latest data from clinical trials and give their opinion on what the data means regarding potential treatment options and identify knowledge gaps requiring further research.
Ep. 1: The ABCs of ADCs
Antibody-Drug Conjugates (ADCs) are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. In this episode you will learn the following:
- How exactly do ADCs work?
- What are the targets for ADCs?
- What are the differences between ADC, MOA, and the differences in some of the ADCs – high DAR, and the controlled bystander effect
- The importance of an optimal diagnostic assay (H-score vs PS2+ vs TPS) NS
- The importance of a correct dosing regimen
- The payload in relation to ADC’s and current ongoing studies.
Featured on this episode:
Dr. Brad Monk
Division of Gynecologic Oncology, Arizona Oncology (US Oncology Network) and the University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph's Hospital Phoenix, USA and Medical Director US Oncology Research Network - Gynecologic Program
Dr. Kathleen Moore
Virginia Kerley Cade Endowed Chair in Cancer Developmental Therapeutics Associate Director Clinical Research, Director, Oklahoma TSET Phase I Program, Stephenson Cancer Center and Associate Professor, Section of Gynecologic Oncology At the University of Oklahoma Health Sciences Center
